Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Neurosci Biobehav Rev ; 159: 105604, 2024 Apr.
Article de Anglais | MEDLINE | ID: mdl-38423195

RÉSUMÉ

Conflicting evidence exists on the relationship between diabetes mellitus (DM) and Alzheimer's disease (AD) biomarkers. Therefore, we conducted a random-effects meta-analysis to evaluate the correlation of glucose metabolism measures (glycated hemoglobin, fasting blood glucose, insulin resistance indices) and DM status with AD biomarkers of amyloid-ß and tau measured by positron emission tomography or cerebrospinal fluid. We selected 37 studies from PubMed and Embase, including 11,694 individuals. More impaired glucose metabolism and DM status were associated with higher tau biomarkers (r=0.11[0.03-0.18], p=0.008; I2=68%), but were not associated with amyloid-ß biomarkers (r=-0.06[-0.13-0.01], p=0.08; I2=81%). Meta-regression revealed that glucose metabolism and DM were specifically associated with tau biomarkers in population settings (p=0.001). Furthermore, more impaired glucose metabolism and DM status were associated with lower amyloid-ß biomarkers in memory clinic settings (p=0.004), and in studies with a higher prevalence of dementia (p<0.001) or lower cognitive scores (p=0.04). These findings indicate that DM is associated with biomarkers of tau but not with amyloid-ß. This knowledge is valuable for improving dementia and DM diagnostics and treatment.


Sujet(s)
Maladie d'Alzheimer , Dysfonctionnement cognitif , Diabète , Humains , Maladie d'Alzheimer/métabolisme , Peptides bêta-amyloïdes , Marqueurs biologiques , Dysfonctionnement cognitif/métabolisme , Glucose , Fragments peptidiques , Tomographie par émission de positons/méthodes , Protéines tau
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...